Which has better valuation & earnings, ZLAB or VALN?

Valneva has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 4.56 -$175.54M -$1.62 N/A Valneva $197.56M 2.59 -$130.33M -$1.87 N/A

Is ZLAB or VALN more profitable?

Zai Lab has a net margin of -39.29% compared to Valneva's net margin of -88.87%. Zai Lab's return on equity of -24.32% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Valneva -88.87% -107.63% -33.02%

Which has better valuation & earnings, VALN or ADMA?

ADMA Biologics has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.59 -$130.33M -$1.87 N/A ADMA Biologics $510.17M 3.95 $146.93M $0.68 12.78

Is VALN or ADMA more profitable?

ADMA Biologics has a net margin of 32.43% compared to Valneva's net margin of -88.87%. ADMA Biologics' return on equity of 39.98% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% ADMA Biologics 32.43% 39.98% 28.08%

Which has better valuation and earnings, VCEL or VALN?

Vericel has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 7.47 $16.52M $0.42 96.17 Valneva $197.56M 2.59 -$130.33M -$1.87 N/A

Is VCEL or VALN more profitable?

Vericel has a net margin of 7.35% compared to Valneva's net margin of -88.87%. Vericel's return on equity of 6.41% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% Valneva -88.87% -107.63% -33.02%

Valneva (VALN) Competitors

$5.40 +0.05 (+0.93%)

As of 04:00 PM Eastern

Compare

VALN vs. NTLA, ZLAB, ADMA, MLYS, and VCEL

Should you buy Valneva stock or one of its competitors? MarketBeat compares Valneva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valneva include Intellia Therapeutics (NTLA), Zai Lab (ZLAB), ADMA Biologics (ADMA), Mineralys Therapeutics (MLYS), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry.

How does Valneva compare to Intellia Therapeutics?

Valneva (NASDAQ:VALN) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Valneva has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.87	N/A
Intellia Therapeutics	$67.67M	31.49	-$412.69M	-$3.54	N/A

Valneva has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Valneva currently has a consensus price target of $11.98, suggesting a potential upside of 121.76%. Intellia Therapeutics has a consensus price target of $20.46, suggesting a potential upside of 34.14%. Given Valneva's higher probable upside, analysts plainly believe Valneva is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Valneva has a net margin of -88.87% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

11.4% of Valneva shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Intellia Therapeutics had 3 more articles in the media than Valneva. MarketBeat recorded 3 mentions for Intellia Therapeutics and 0 mentions for Valneva. Intellia Therapeutics' average media sentiment score of 0.42 beat Valneva's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Valneva	Neutral
Intellia Therapeutics	Neutral

Summary

Intellia Therapeutics beats Valneva on 9 of the 17 factors compared between the two stocks.

How does Valneva compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Zai Lab has a net margin of -39.29% compared to Valneva's net margin of -88.87%. Zai Lab's return on equity of -24.32% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Valneva	-88.87%	-107.63%	-33.02%

Zai Lab has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Valneva has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

In the previous week, Valneva's average media sentiment score of 0.00 beat Zai Lab's score of -0.27 indicating that Valneva is being referred to more favorably in the news media.

Company	Overall Sentiment
Zai Lab	Neutral
Valneva	Neutral

Valneva has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.56	-$175.54M	-$1.62	N/A
Valneva	$197.56M	2.59	-$130.33M	-$1.87	N/A

Zai Lab currently has a consensus target price of $45.83, suggesting a potential upside of 147.88%. Valneva has a consensus target price of $11.98, suggesting a potential upside of 121.76%. Given Zai Lab's stronger consensus rating and higher possible upside, research analysts plainly believe Zai Lab is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Zai Lab beats Valneva on 11 of the 16 factors compared between the two stocks.

How does Valneva compare to ADMA Biologics?

Valneva (NASDAQ:VALN) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Valneva has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

ADMA Biologics has a net margin of 32.43% compared to Valneva's net margin of -88.87%. ADMA Biologics' return on equity of 39.98% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
ADMA Biologics	32.43%	39.98%	28.08%

Valneva currently has a consensus price target of $11.98, indicating a potential upside of 121.76%. ADMA Biologics has a consensus price target of $19.67, indicating a potential upside of 126.31%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADMA Biologics had 35 more articles in the media than Valneva. MarketBeat recorded 35 mentions for ADMA Biologics and 0 mentions for Valneva. ADMA Biologics' average media sentiment score of 0.06 beat Valneva's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Valneva	Neutral
ADMA Biologics	Neutral

ADMA Biologics has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.87	N/A
ADMA Biologics	$510.17M	3.95	$146.93M	$0.68	12.78

11.4% of Valneva shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats Valneva on 13 of the 15 factors compared between the two stocks.

How does Valneva compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Valneva has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Valneva	$197.56M	2.59	-$130.33M	-$1.87	N/A

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mineralys Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Valneva has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

Mineralys Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Mineralys Therapeutics' return on equity of -27.92% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Valneva	-88.87%	-107.63%	-33.02%

Mineralys Therapeutics presently has a consensus price target of $49.33, indicating a potential upside of 92.63%. Valneva has a consensus price target of $11.98, indicating a potential upside of 121.76%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Mineralys Therapeutics had 13 more articles in the media than Valneva. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 0 mentions for Valneva. Mineralys Therapeutics' average media sentiment score of 0.41 beat Valneva's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Mineralys Therapeutics	Neutral
Valneva	Neutral

Summary

Mineralys Therapeutics beats Valneva on 9 of the 15 factors compared between the two stocks.

How does Valneva compare to Vericel?

Vericel (NASDAQ:VCEL) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Vericel has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.47	$16.52M	$0.42	96.17
Valneva	$197.56M	2.59	-$130.33M	-$1.87	N/A

11.4% of Valneva shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vericel has a net margin of 7.35% compared to Valneva's net margin of -88.87%. Vericel's return on equity of 6.41% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Valneva	-88.87%	-107.63%	-33.02%

Vericel currently has a consensus target price of $52.50, suggesting a potential upside of 29.98%. Valneva has a consensus target price of $11.98, suggesting a potential upside of 121.76%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Vericel had 2 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Vericel and 0 mentions for Valneva. Valneva's average media sentiment score of 0.00 beat Vericel's score of -2.00 indicating that Valneva is being referred to more favorably in the news media.

Company	Overall Sentiment
Vericel	Very Negative
Valneva	Neutral

Vericel has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Valneva has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

Summary

Vericel beats Valneva on 11 of the 16 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VALN vs. The Competition

Export

Metric	Valneva	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$507.64M	$8.15B	$6.45B	$12.39B
Dividend Yield	N/A	2.60%	2.69%	5.83%
P/E Ratio	-2.89	12.30	21.07	22.20
Price / Sales	2.59	6.99	530.36	110.15
Price / Cash	N/A	16.83	44.82	54.51
Price / Book	3.88	3.21	10.79	6.50
Net Income	-$130.33M	$226.25M	$3.56B	$336.88M
7 Day Performance	0.75%	-3.57%	1.67%	-0.22%
1 Month Performance	-8.94%	-3.72%	0.43%	0.77%
1 Year Performance	-2.88%	1.93%	32.84%	31.57%

Valneva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VALN Valneva	1.5964 of 5 stars	$5.40 +0.9%	$11.98 +121.8%	-5.4%	$507.64M	$197.56M	N/A	700	Positive News
NTLA Intellia Therapeutics	3.1027 of 5 stars	$14.48 -2.9%	$20.46 +41.3%	+71.2%	$2.02B	$67.67M	N/A	600	Gap Down
ZLAB Zai Lab	2.1098 of 5 stars	$17.74 +0.1%	$45.83 +158.4%	-46.5%	$2.01B	$460.16M	N/A	1,784
ADMA ADMA Biologics	4.5006 of 5 stars	$8.59 +1.0%	$19.67 +129.0%	-51.7%	$1.99B	$510.17M	12.63	530	Trending News
MLYS Mineralys Therapeutics	3.8025 of 5 stars	$23.95 +0.1%	$49.33 +106.0%	+88.2%	$1.98B	N/A	N/A	28

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VALN) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valneva (VALN) Competitors

VALN vs. NTLA, ZLAB, ADMA, MLYS, and VCEL

How does Valneva compare to Intellia Therapeutics?

Summary

How does Valneva compare to Zai Lab?

Summary

How does Valneva compare to ADMA Biologics?

Summary

How does Valneva compare to Mineralys Therapeutics?

Summary

How does Valneva compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valneva (VALN) Competitors

VALN vs. NTLA, ZLAB, ADMA, MLYS, and VCEL

How does Valneva compare to Intellia Therapeutics?

Which has higher earnings & valuation, VALN or NTLA?

Which has more risk and volatility, VALN or NTLA?

Do analysts recommend VALN or NTLA?

Is VALN or NTLA more profitable?

Do institutionals & insiders hold more shares of VALN or NTLA?

Does the media favor VALN or NTLA?

Summary

How does Valneva compare to Zai Lab?

Is ZLAB or VALN more profitable?

Which has more risk & volatility, ZLAB or VALN?

Does the media prefer ZLAB or VALN?

Which has better valuation & earnings, ZLAB or VALN?

Do analysts recommend ZLAB or VALN?

Do institutionals and insiders hold more shares of ZLAB or VALN?

Summary

How does Valneva compare to ADMA Biologics?

Which has more volatility & risk, VALN or ADMA?

Is VALN or ADMA more profitable?

Do analysts recommend VALN or ADMA?

Does the media favor VALN or ADMA?

Which has better valuation & earnings, VALN or ADMA?

Do institutionals & insiders have more ownership in VALN or ADMA?

Summary

How does Valneva compare to Mineralys Therapeutics?

Which has preferable valuation and earnings, MLYS or VALN?

Do institutionals and insiders believe in MLYS or VALN?

Which has more volatility & risk, MLYS or VALN?

Is MLYS or VALN more profitable?

Do analysts rate MLYS or VALN?

Does the media refer more to MLYS or VALN?

Summary

How does Valneva compare to Vericel?

Which has better valuation and earnings, VCEL or VALN?

Do institutionals & insiders have more ownership in VCEL or VALN?

Is VCEL or VALN more profitable?

Do analysts rate VCEL or VALN?

Does the media prefer VCEL or VALN?

Which has more volatility and risk, VCEL or VALN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools